Roche to discontinue production of nelfinavir and saquinavir 200 mg hard capsules
Roche Laboratories have announced that they intend to discontinue the production of nelfinavir powder and tablets globally when the European patent ends on 23 January 2013.
The decision has been made due to the extremely low use together with the availability of alternative treatments with improved risk/benefit profiles.
Less than 200 people are estimated to still be using the Roche product globally.
Additionally, the 200 mg formulation of saquinavir (Invirase hard capsules) will no longer be available in the UK.
The company will continue to manufacture the 500 mg film-coated tablet formulation of saquinavir and also continue to produce T-20 (enfuvirtide, Fuzeon), irrespective of the current low level of usage.
Source: Press letter from Roche/Genentech. (20 July 2012).